Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.

Anisimov VN, Khavinson VKh, Alimova IN, Semchenko AV, Yashin AI

Bulletin of experimental biology and medicine1 Aug 2002Cited by 3 (Europe PMC)

PMID12459848DOI10.1023/a:1021104819170PepBankPUB-12459848

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon prolonged the average lifetime by 13.5%.
In plain wordsIn mice prone to breast cancer, Epithalon lengthened average lifespan.
Peptide
Epitalon
Outcome
IncreaseAverage lifespan
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Mortality · Aging and longevity
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Increase in average lifespan
13.5%
Epithalon
Source sentences
Summary
Epithalon prolonged the average and maximum lifetimes of mice by 13.5 (p<0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984801
02AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon prolonged the maximum lifetime by 13.9%.
In plain wordsIn mice prone to breast cancer, Epithalon lengthened maximum lifespan.
Peptide
Epitalon
Outcome
IncreaseMaximum lifespan
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Mortality · Aging and longevity
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Increase in maximum lifespan
13.9%
Epithalon
Source sentences
Summary
Epithalon prolonged the average and maximum lifetimes of mice by 13.5 (p<0.05) and 13.9%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984802
03AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon prolonged the average lifetime of animals without neoplasms by 34.2%.
In plain wordsIn mice prone to breast cancer, Epithalon lengthened average lifespan of animals that had no tumors.
Peptide
Epitalon
Outcome
IncreaseAverage lifespan of mice without neoplasms
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Mortality · Aging and longevity
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Increase in lifespan without neoplasms
34.2%
Epithalon
Source sentences
Summary
The peptide prolonged the average lifetime of animals without neoplasms (by 34.2%, p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984803
04AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon decelerated the development of age-related disturbances in reproductive activity.
In plain wordsIn mice prone to breast cancer, Epithalon slowed age-related decline in reproductive activity.
Peptide
Epitalon
Outcome
DecreaseAge-related disturbances in reproductive activity
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Aging markers · Reproductive and sexual health
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Source sentences
Summary
Epithalon decelerated the development of age-related disturbances in reproductive activity
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984804
05AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon decreased the incidence of breast adenocarcinomas.
In plain wordsIn mice prone to breast cancer, Epithalon lowered how often breast tumors appeared.
Peptide
Epitalon
Outcome
DecreaseIncidence of breast adenocarcinomas
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Source sentences
Summary
The peptide decreased the incidence of breast adenocarcinomas, lungs metastases (by 1.6 times, p<0.05), and multiple tumors (by 2 times).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984805
06AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon decreased lung metastases by 1.6 times.
In plain wordsIn mice prone to breast cancer, Epithalon lowered the number of lung metastases.
Peptide
Epitalon
Outcome
DecreaseLung metastases
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Reduction in lung metastases
1.6 times
Epithalon
Source sentences
Summary
The peptide decreased the incidence of breast adenocarcinomas, lungs metastases (by 1.6 times, p<0.05), and multiple tumors (by 2 times).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984806
07AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon decreased multiple tumors by 2 times.
In plain wordsIn mice prone to breast cancer, Epithalon lowered the number of animals with multiple tumors.
Peptide
Epitalon
Outcome
DecreaseMultiple tumors
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Reduction in multiple tumors
2 times
Epithalon
Source sentences
Summary
The peptide decreased the incidence of breast adenocarcinomas, lungs metastases (by 1.6 times, p<0.05), and multiple tumors (by 2 times).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984807
08AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon increased the number of mice without breast tumors 3.7-fold.
In plain wordsIn mice prone to breast cancer, Epithalon increased the number of animals free of breast tumors.
Peptide
Epitalon
Outcome
IncreaseMice without breast tumors
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Increase in mice without breast tumors
3.7 fold
Epithalon
Source sentences
Summary
Epithalon 3.7-fold increased the number of mice without breast tumors (p<0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984808
09AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon decreased the number of animals with 6 or more breast tumors by 3 times.
In plain wordsIn mice prone to breast cancer, Epithalon lowered the number of animals with many breast tumors.
Peptide
Epitalon
Outcome
DecreaseMice with 6 or more breast tumors
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Reduction in mice with 6 or more tumors
3 times
Epithalon
Source sentences
Summary
while the number of animals with 6 or more breast tumors decreased by 3 times (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984809
10AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon prolonged the lifetime of mice with breast tumors by 1.4 times.
In plain wordsIn mice prone to breast cancer, Epithalon lengthened the lifespan of animals that had breast tumors.
Peptide
Epitalon
Outcome
IncreaseLifespan of mice with breast tumors
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Mortality · Aging and longevity
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Measurements
Increase in lifespan with tumors
1.4 times
Epithalon
Source sentences
Summary
Epithalon prolonged the lifetime of mice with breast tumors by 1.4 times (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death.
Report a problemFND-1245984810
11AnimalAnimal study (in vivo)Efficacy outcome
In HER-2/neu transgenic mice, Epithalon suppressed the formation of neoplasms.
In plain wordsIn mice prone to breast cancer, Epithalon reduced the formation of tumors.
Peptide
Epitalon
Outcome
DecreaseFormation of neoplasms
Study
mousen: not reported in source
HER-2/neu transgenic FVB/N mice
Outcome group
Tumor growth · Cancer
Studied dose
1 mg · subcutaneous · from the 2nd month of life to deathAs given in this study (mouse).
Source sentences
Summary
suppressed the formation of neoplasms
Report a problemFND-1245984811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.